Nucana Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Nucana Plc, a foreign private issuer, on December 10, 2025. The report covers "Other Events" occurring during the month of December 2025. The company is headquartered in Edinburgh, United Kingdom.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate event rather than financial performance.
Material Changes
On December 10, 2025, the Company announced the presentation of latest clinical data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2025. The data pertains to patients with PD-1 inhibitor-resistant-metastatic melanoma treated with NUC-7738 in combination with pembrolizumab.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) by reference but explicitly states that the information within the exhibit is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934. No specific financial guidance, management commentary on future outlook, or new risk factors are detailed in the body of this Form 6-K.
Key Facts for Investor Verification
- Verify the specific clinical outcomes and statistical significance of the NUC-7738 combination therapy data presented at ESMO 2025.
- Review the full text of the press release attached as Exhibit 99.1 for detailed trial results.
- Confirm the regulatory status and development timeline for NUC-7738 following this data presentation.
- Note that the interim Chief Financial Officer, Ian Webster, signed the report on behalf of the registrant.